NICE recommends Osimertinib (Tagrisso®) for EGFR+ Stage 1b–3A NSCLC within the Cancer Drugs Fund

NICE recently published final draft guidance recommending osimertinib (Tagrisso®), a 3rd generation EGFR-TKI, for use in early-stage EGFR T790M mutation-positive NSCLC patients who have progressed on previous EGFR-targeted therapies and who have had their tumor surgically resected. Surgical removal of tumors is the preferred treatment option for many patients with early-stage NSCLC because it has a relatively high potential for curing the disease. However, the cancer still reoccurs in about 45% of people who have this treatment and effective neoadjuvant and adjuvant treatments are under thorough investigation. There are currently no targeted adjuvant treatments available in England for NSCLC patients...